32097 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Millipore etoricoxib
    Relative expression of RANK-L/OPG and extent of hPDL fibroblast-mediated osteoclastogenesis. (a) RANK-L expression according to Western blot densitometry ( N = 7), (b) sRANK-L and (c) OPG protein secretion according to ELISA ( N = 2, n = 6), and (d, e) osteoclastogenesis after coculture with RAW264.7 cells (TRAP staining and mono- and multinucleated osteoclast precursor and osteoclast-like TRAP-positive cells in red, N = 2, n = 6), given as normalized x-fold induction relative to 0 μ M <t>etoricoxib</t> without mechanical strain. Asterisms without bars indicate significant differences to the corresponding 0 μ M control. Abbreviations: see manuscript text. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, and ∗∗∗ p ≤ 0.001. AU: arbitrary units. Bars show mean and standard deviation; TRAP: tartrate-resistant acid phosphatase.
    Etoricoxib, supplied by Millipore, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/etoricoxib/product/Millipore
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    etoricoxib - by Bioz Stars, 2022-12
    94/100 stars
      Buy from Supplier

    93
    Cayman Chemical sars cov 2 neutralizing antibody detection elisa kit
    Serum levels of specific antibodies targeting <t>SARS-CoV-2</t> structural proteins: nucleocapsid protein ( n ), spike protein domain S1 ( s1 ) and envelope protein ( e ). Human sera were collected from three groups of patients: SARS-CoV-2, patients after confirmed SARS-CoV-2 infection; Healthy, blood donors without confirmed SARS-CoV-2 infection, blood collected between March and June 2020; Historical, serum samples collected from healthy volunteers in the years 2010–2017. All samples were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. [ 24, 25 ]). Normalized ELISA units are presented: vertical lines in the boxes, median; boxes, values within second and third quartile; whiskers, sd ; dots at the side of each box, real distribution of individual reads; *, ** and ***, difference between SARS-CoV-2 and Healthy statistically significant in non-parametric ANOVA and Kruskal–Wallis test ( P
    Sars Cov 2 Neutralizing Antibody Detection Elisa Kit, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 neutralizing antibody detection elisa kit/product/Cayman Chemical
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 neutralizing antibody detection elisa kit - by Bioz Stars, 2022-12
    93/100 stars
      Buy from Supplier

    Image Search Results


    Relative expression of RANK-L/OPG and extent of hPDL fibroblast-mediated osteoclastogenesis. (a) RANK-L expression according to Western blot densitometry ( N = 7), (b) sRANK-L and (c) OPG protein secretion according to ELISA ( N = 2, n = 6), and (d, e) osteoclastogenesis after coculture with RAW264.7 cells (TRAP staining and mono- and multinucleated osteoclast precursor and osteoclast-like TRAP-positive cells in red, N = 2, n = 6), given as normalized x-fold induction relative to 0 μ M etoricoxib without mechanical strain. Asterisms without bars indicate significant differences to the corresponding 0 μ M control. Abbreviations: see manuscript text. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, and ∗∗∗ p ≤ 0.001. AU: arbitrary units. Bars show mean and standard deviation; TRAP: tartrate-resistant acid phosphatase.

    Journal: Mediators of Inflammation

    Article Title: Effects of the Highly COX-2-Selective Analgesic NSAID Etoricoxib on Human Periodontal Ligament Fibroblasts during Compressive Orthodontic Mechanical Strain

    doi: 10.1155/2019/2514956

    Figure Lengend Snippet: Relative expression of RANK-L/OPG and extent of hPDL fibroblast-mediated osteoclastogenesis. (a) RANK-L expression according to Western blot densitometry ( N = 7), (b) sRANK-L and (c) OPG protein secretion according to ELISA ( N = 2, n = 6), and (d, e) osteoclastogenesis after coculture with RAW264.7 cells (TRAP staining and mono- and multinucleated osteoclast precursor and osteoclast-like TRAP-positive cells in red, N = 2, n = 6), given as normalized x-fold induction relative to 0 μ M etoricoxib without mechanical strain. Asterisms without bars indicate significant differences to the corresponding 0 μ M control. Abbreviations: see manuscript text. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, and ∗∗∗ p ≤ 0.001. AU: arbitrary units. Bars show mean and standard deviation; TRAP: tartrate-resistant acid phosphatase.

    Article Snippet: For RT-qPCR analyses as well as LDH/MTT assays, hPDL fibroblasts in six experimental groups with 9 wells (n = 9) on three plates (N = 3) each were, respectively, incubated with either 0 μ M (control), 3.29 μ M, or 5.49 μ M etoricoxib (Etoricoxib VETRANAL™ analytical standard: 32097 FLUKA, Sigma-Aldrich®, Taufkirchen, Germany) for 72 h, corresponding to assumed local concentrations reached in the PDL during normal and subtoxic clinical dosing in man [ , ], with or without (3/3 wells per plate) compressive mechanical strain of 2 g/cm2 for 48 h after a 24 h preincubation phase by means of a glass disc according to a published and well-established protocol for the simulation of compressive orthodontic mechanical strain [ , ] ( ).

    Techniques: Expressing, Western Blot, Enzyme-linked Immunosorbent Assay, Staining, Standard Deviation

    Relative expression of alkaline phosphatase (a, b) (bone formation), as well as of VEGF-A (c) (angiogenesis) and P4HA1, COL1A2, and FN1 (d), (e), and (f), respectively (extracellular matrix remodeling), except for ELISA as normalized x-fold induction relative to 0 μ M etoricoxib without mechanical strain. Abbreviations: see manuscript text. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, and ∗∗∗ p ≤ 0.001. AU: arbitrary units. Bars show mean and standard deviation. ELISA: N = 2, n = 6; RT-qPCR: N = 3, n = 9; ELISA: enzyme-linked immunosorbent assay; RT-qPCR: real-time reverse transcription quantitative polymerase chain reaction.

    Journal: Mediators of Inflammation

    Article Title: Effects of the Highly COX-2-Selective Analgesic NSAID Etoricoxib on Human Periodontal Ligament Fibroblasts during Compressive Orthodontic Mechanical Strain

    doi: 10.1155/2019/2514956

    Figure Lengend Snippet: Relative expression of alkaline phosphatase (a, b) (bone formation), as well as of VEGF-A (c) (angiogenesis) and P4HA1, COL1A2, and FN1 (d), (e), and (f), respectively (extracellular matrix remodeling), except for ELISA as normalized x-fold induction relative to 0 μ M etoricoxib without mechanical strain. Abbreviations: see manuscript text. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, and ∗∗∗ p ≤ 0.001. AU: arbitrary units. Bars show mean and standard deviation. ELISA: N = 2, n = 6; RT-qPCR: N = 3, n = 9; ELISA: enzyme-linked immunosorbent assay; RT-qPCR: real-time reverse transcription quantitative polymerase chain reaction.

    Article Snippet: For RT-qPCR analyses as well as LDH/MTT assays, hPDL fibroblasts in six experimental groups with 9 wells (n = 9) on three plates (N = 3) each were, respectively, incubated with either 0 μ M (control), 3.29 μ M, or 5.49 μ M etoricoxib (Etoricoxib VETRANAL™ analytical standard: 32097 FLUKA, Sigma-Aldrich®, Taufkirchen, Germany) for 72 h, corresponding to assumed local concentrations reached in the PDL during normal and subtoxic clinical dosing in man [ , ], with or without (3/3 wells per plate) compressive mechanical strain of 2 g/cm2 for 48 h after a 24 h preincubation phase by means of a glass disc according to a published and well-established protocol for the simulation of compressive orthodontic mechanical strain [ , ] ( ).

    Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Standard Deviation, Quantitative RT-PCR, Real-time Polymerase Chain Reaction

    Apoptosis and necrosis (FACS), cell viability (MTT), and cytotoxicity (LDH) of hPDL fibroblasts incubated with rising etoricoxib concentrations with and without mechanical strain. (a) Representative FACS distributions ( M ± SD, positive cells relative to total cells (%)) of apoptotic (Q4, FITC annexin V), necrotic (Q2, propidium iodide), and viable cells (Q3). N = 3, n = 6. (b) Cell viability as assessed by MTT assay; N = 3, n = 9. (c) Cytotoxicity assessed by LDH assay; N = 3, n = 9. All values given as normalized x-fold induction relative to 0 μ M etoricoxib without mechanical strain. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, and ∗∗∗ p ≤ 0.001. AU: arbitrary units. Bars show mean and standard deviation. PerCP-Cy5-5-H: peridinin-chlorophyll-protein complex channel (propidium iodide, necrosis); FITC-H: fluorescein thiocyanate channel (annexin V, apoptosis); MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid; LDH: lactate dehydrogenase.

    Journal: Mediators of Inflammation

    Article Title: Effects of the Highly COX-2-Selective Analgesic NSAID Etoricoxib on Human Periodontal Ligament Fibroblasts during Compressive Orthodontic Mechanical Strain

    doi: 10.1155/2019/2514956

    Figure Lengend Snippet: Apoptosis and necrosis (FACS), cell viability (MTT), and cytotoxicity (LDH) of hPDL fibroblasts incubated with rising etoricoxib concentrations with and without mechanical strain. (a) Representative FACS distributions ( M ± SD, positive cells relative to total cells (%)) of apoptotic (Q4, FITC annexin V), necrotic (Q2, propidium iodide), and viable cells (Q3). N = 3, n = 6. (b) Cell viability as assessed by MTT assay; N = 3, n = 9. (c) Cytotoxicity assessed by LDH assay; N = 3, n = 9. All values given as normalized x-fold induction relative to 0 μ M etoricoxib without mechanical strain. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, and ∗∗∗ p ≤ 0.001. AU: arbitrary units. Bars show mean and standard deviation. PerCP-Cy5-5-H: peridinin-chlorophyll-protein complex channel (propidium iodide, necrosis); FITC-H: fluorescein thiocyanate channel (annexin V, apoptosis); MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid; LDH: lactate dehydrogenase.

    Article Snippet: For RT-qPCR analyses as well as LDH/MTT assays, hPDL fibroblasts in six experimental groups with 9 wells (n = 9) on three plates (N = 3) each were, respectively, incubated with either 0 μ M (control), 3.29 μ M, or 5.49 μ M etoricoxib (Etoricoxib VETRANAL™ analytical standard: 32097 FLUKA, Sigma-Aldrich®, Taufkirchen, Germany) for 72 h, corresponding to assumed local concentrations reached in the PDL during normal and subtoxic clinical dosing in man [ , ], with or without (3/3 wells per plate) compressive mechanical strain of 2 g/cm2 for 48 h after a 24 h preincubation phase by means of a glass disc according to a published and well-established protocol for the simulation of compressive orthodontic mechanical strain [ , ] ( ).

    Techniques: FACS, MTT Assay, Incubation, Lactate Dehydrogenase Assay, Standard Deviation

    Relative secretion of prostaglandin E 2 (a) as well as expression of proinflammatory genes cyclooxygenase 2 (b) and interleukin 6 (c) as normalized x-fold induction relative to 0 μ M etoricoxib without mechanical strain. Asterisms without bars indicate significant differences to the corresponding 0 μ M control with or without strain. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, and ∗∗∗ p ≤ 0.001. AU: arbitrary units. Bars show mean and standard deviation. PG-E 2 ELISA: N = 2, n = 6; RT-qPCR: N = 3, n = 9.

    Journal: Mediators of Inflammation

    Article Title: Effects of the Highly COX-2-Selective Analgesic NSAID Etoricoxib on Human Periodontal Ligament Fibroblasts during Compressive Orthodontic Mechanical Strain

    doi: 10.1155/2019/2514956

    Figure Lengend Snippet: Relative secretion of prostaglandin E 2 (a) as well as expression of proinflammatory genes cyclooxygenase 2 (b) and interleukin 6 (c) as normalized x-fold induction relative to 0 μ M etoricoxib without mechanical strain. Asterisms without bars indicate significant differences to the corresponding 0 μ M control with or without strain. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, and ∗∗∗ p ≤ 0.001. AU: arbitrary units. Bars show mean and standard deviation. PG-E 2 ELISA: N = 2, n = 6; RT-qPCR: N = 3, n = 9.

    Article Snippet: For RT-qPCR analyses as well as LDH/MTT assays, hPDL fibroblasts in six experimental groups with 9 wells (n = 9) on three plates (N = 3) each were, respectively, incubated with either 0 μ M (control), 3.29 μ M, or 5.49 μ M etoricoxib (Etoricoxib VETRANAL™ analytical standard: 32097 FLUKA, Sigma-Aldrich®, Taufkirchen, Germany) for 72 h, corresponding to assumed local concentrations reached in the PDL during normal and subtoxic clinical dosing in man [ , ], with or without (3/3 wells per plate) compressive mechanical strain of 2 g/cm2 for 48 h after a 24 h preincubation phase by means of a glass disc according to a published and well-established protocol for the simulation of compressive orthodontic mechanical strain [ , ] ( ).

    Techniques: Expressing, Standard Deviation, Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR

    Serum levels of specific antibodies targeting SARS-CoV-2 structural proteins: nucleocapsid protein ( n ), spike protein domain S1 ( s1 ) and envelope protein ( e ). Human sera were collected from three groups of patients: SARS-CoV-2, patients after confirmed SARS-CoV-2 infection; Healthy, blood donors without confirmed SARS-CoV-2 infection, blood collected between March and June 2020; Historical, serum samples collected from healthy volunteers in the years 2010–2017. All samples were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. [ 24, 25 ]). Normalized ELISA units are presented: vertical lines in the boxes, median; boxes, values within second and third quartile; whiskers, sd ; dots at the side of each box, real distribution of individual reads; *, ** and ***, difference between SARS-CoV-2 and Healthy statistically significant in non-parametric ANOVA and Kruskal–Wallis test ( P

    Journal: The Journal of General Virology

    Article Title: Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples

    doi: 10.1099/jgv.0.001692

    Figure Lengend Snippet: Serum levels of specific antibodies targeting SARS-CoV-2 structural proteins: nucleocapsid protein ( n ), spike protein domain S1 ( s1 ) and envelope protein ( e ). Human sera were collected from three groups of patients: SARS-CoV-2, patients after confirmed SARS-CoV-2 infection; Healthy, blood donors without confirmed SARS-CoV-2 infection, blood collected between March and June 2020; Historical, serum samples collected from healthy volunteers in the years 2010–2017. All samples were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. [ 24, 25 ]). Normalized ELISA units are presented: vertical lines in the boxes, median; boxes, values within second and third quartile; whiskers, sd ; dots at the side of each box, real distribution of individual reads; *, ** and ***, difference between SARS-CoV-2 and Healthy statistically significant in non-parametric ANOVA and Kruskal–Wallis test ( P

    Article Snippet: The SARS-CoV-2 Neutralizing Antibody Detection ELISA kit (Cayman Chemicals, Ann Arbor, MI, USA, cat. no 502070) was used to assess inhibition of binding of S protein to ACE2 receptor.

    Techniques: Infection, Enzyme-linked Immunosorbent Assay

    Nucleocapsid ( n ) and spike protein domain ( s1 )-specific IgG antibodies in SARS-CoV-2-infected patients in time. Serum samples were collected from SARS-CoV-2-infected patients available for multiple sampling and time points were fitted to patients’ availability. Sera were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. [ 24, 25 ]). Individual values for each patient and time point are presented. Patients are identified by numbers in accordance with Table S1. Time points are presented as approximate weeks after infection. The shaded areas represent the 95 % confidence level interval for predictions from a linear model.

    Journal: The Journal of General Virology

    Article Title: Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples

    doi: 10.1099/jgv.0.001692

    Figure Lengend Snippet: Nucleocapsid ( n ) and spike protein domain ( s1 )-specific IgG antibodies in SARS-CoV-2-infected patients in time. Serum samples were collected from SARS-CoV-2-infected patients available for multiple sampling and time points were fitted to patients’ availability. Sera were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. [ 24, 25 ]). Individual values for each patient and time point are presented. Patients are identified by numbers in accordance with Table S1. Time points are presented as approximate weeks after infection. The shaded areas represent the 95 % confidence level interval for predictions from a linear model.

    Article Snippet: The SARS-CoV-2 Neutralizing Antibody Detection ELISA kit (Cayman Chemicals, Ann Arbor, MI, USA, cat. no 502070) was used to assess inhibition of binding of S protein to ACE2 receptor.

    Techniques: Infection, Sampling, Enzyme-linked Immunosorbent Assay

    SARS-CoV-2 structural proteins.

    Journal: The Journal of General Virology

    Article Title: Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples

    doi: 10.1099/jgv.0.001692

    Figure Lengend Snippet: SARS-CoV-2 structural proteins.

    Article Snippet: The SARS-CoV-2 Neutralizing Antibody Detection ELISA kit (Cayman Chemicals, Ann Arbor, MI, USA, cat. no 502070) was used to assess inhibition of binding of S protein to ACE2 receptor.

    Techniques:

    Medical conditions correlating with the induction of antibodies targeting SARS-CoV-2 structural proteins in patients after confirmed infection with SARS-CoV-2. All samples were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. [ 24, 25 ]). Normalized ELISA units are presented: vertical lines in the boxes, median; boxes, values within second and third quartile; whiskers, sd ; dots at the side of each box, real distribution of individual reads. Statistical analysis by non-parametric ANOVA and Kruskal–Wallis test ( a ) or by Mann–Whitney U test ( b, c, d ). (a) Severity of COVID-19 correlated to increased protein-specific antibody production. Patients were assigned to the groups by the physicians, with regard to symptoms, required treatment procedures, and length of the disease. (b) Rise of body temperature during infection over 38 °C was a predictor of SARS-CoV-2 structural protein-specific antibody induction. Samples from patients after infection were grouped according to observed (positive) or not observed (negative) body temperature over 38 °C. (c) Breathing difficulties during infection was an inadequate predictor of SARS-CoV-2 structural protein-specific antibody induction. Samples from patients after infection were grouped according to observed (positive) or not observed (negative) breathing difficulties. (d) Cough during infection as a positive predictor of SARS-CoV-2 structural protein-specific antibody induction. Samples from patients after infection were grouped according to observed (positive) or not observed (negative) cough in patients.

    Journal: The Journal of General Virology

    Article Title: Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples

    doi: 10.1099/jgv.0.001692

    Figure Lengend Snippet: Medical conditions correlating with the induction of antibodies targeting SARS-CoV-2 structural proteins in patients after confirmed infection with SARS-CoV-2. All samples were tested by ELISA on SARS-CoV-2 protein-covered plates, and normalized using reference serum (as described by Miura et al. [ 24, 25 ]). Normalized ELISA units are presented: vertical lines in the boxes, median; boxes, values within second and third quartile; whiskers, sd ; dots at the side of each box, real distribution of individual reads. Statistical analysis by non-parametric ANOVA and Kruskal–Wallis test ( a ) or by Mann–Whitney U test ( b, c, d ). (a) Severity of COVID-19 correlated to increased protein-specific antibody production. Patients were assigned to the groups by the physicians, with regard to symptoms, required treatment procedures, and length of the disease. (b) Rise of body temperature during infection over 38 °C was a predictor of SARS-CoV-2 structural protein-specific antibody induction. Samples from patients after infection were grouped according to observed (positive) or not observed (negative) body temperature over 38 °C. (c) Breathing difficulties during infection was an inadequate predictor of SARS-CoV-2 structural protein-specific antibody induction. Samples from patients after infection were grouped according to observed (positive) or not observed (negative) breathing difficulties. (d) Cough during infection as a positive predictor of SARS-CoV-2 structural protein-specific antibody induction. Samples from patients after infection were grouped according to observed (positive) or not observed (negative) cough in patients.

    Article Snippet: The SARS-CoV-2 Neutralizing Antibody Detection ELISA kit (Cayman Chemicals, Ann Arbor, MI, USA, cat. no 502070) was used to assess inhibition of binding of S protein to ACE2 receptor.

    Techniques: Infection, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

    Correlations between serum levels of specific antibodies targeting SARS-CoV-2 structural proteins N, S1 and E in (a) SARS-CoV-2- patients with confirmed SARS-CoV-2 infection; ( b ) Healthy, blood donors without confirmed SARS-CoV-2 infection, blood collected between March and June 2020; ( c ) Historical, serum samples collected from healthy volunteers in the years 2010–2017. Normalized ELISA units are compared, P -values calculated by Pearson correlation are presented. Red, strong correlation; blue, weak correlation. Linear regression was used.

    Journal: The Journal of General Virology

    Article Title: Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples

    doi: 10.1099/jgv.0.001692

    Figure Lengend Snippet: Correlations between serum levels of specific antibodies targeting SARS-CoV-2 structural proteins N, S1 and E in (a) SARS-CoV-2- patients with confirmed SARS-CoV-2 infection; ( b ) Healthy, blood donors without confirmed SARS-CoV-2 infection, blood collected between March and June 2020; ( c ) Historical, serum samples collected from healthy volunteers in the years 2010–2017. Normalized ELISA units are compared, P -values calculated by Pearson correlation are presented. Red, strong correlation; blue, weak correlation. Linear regression was used.

    Article Snippet: The SARS-CoV-2 Neutralizing Antibody Detection ELISA kit (Cayman Chemicals, Ann Arbor, MI, USA, cat. no 502070) was used to assess inhibition of binding of S protein to ACE2 receptor.

    Techniques: Infection, Enzyme-linked Immunosorbent Assay